Navigation Links
Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
Date:5/11/2011

affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter and ViroPharma to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin and Cinryze®. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees. ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE). ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroP
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
2. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
3. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
4. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
5. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
6. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
7. Halozyme Therapeutics Realigns Management
8. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
9. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
10. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... York , July 30, 2015 ... its latest report titled, "Continuous Glucose Monitoring Systems Market: ... According to the report, the global continuous glucose monitoring ... 2014 and is expected to reach US$ 788.4 Mn ... forecast period, 2015 to 2020. Global continuous ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... The National Community Pharmacists Association (NCPA) expressed strong ... launched by the U.S. Senate Special Committee on ... Pharmalot . (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) ... response, NCPA President Joseph H. Harmison, PD and Arlington, ...
... premier provider of economic ultrasound solutions, today announced the ... proprietary repair technology not previously available in the U.S. ... repair services designed to counter a growing emphasis in ... industry has been moving away from repairing customers, probes ...
Cached Medicine Technology:NCPA Commends Senate Aging Committee for Launching CVS Caremark Investigation to Examine Alleged Harm to Seniors, Medicare 2MedPro Imaging Launches Ultrasound Transducer Repair Division 2
(Date:7/31/2015)... ... ... Girl Scouts of Historic Georgia and Peach State Health Plan are teaming ... Friend First" program. Representatives from Peach State Health Plan presented a $10,000 check for ... our parent company, Centene Corporation, are dedicated to raising anti-bullying awareness. We are very ...
(Date:7/31/2015)... , ... July 31, 2015 , ... The 2015 ALS ... Major League Baseball and the Boston Red Sox honor Ice Bucket co-founders Pat Quinn ... MLB is donating $100,000 to further collaborative efforts among the ALS organizations to find ...
(Date:7/31/2015)... Toledo, Ohio (PRWEB) , ... July 31, 2015 ... ... U.S. District Court for the Northern District of Ohio, Western Division (Case No. ... complaint (Case No: 3:15-cv-00397), the women experienced spontaneous migration of their Implanon® implants, ...
(Date:7/31/2015)... NY and Rockport, ME (PRWEB) , ... July 31, 2015 , ... The alarm was ... op. , Glancing out of the window, he recalled that his equipment was set ... Chrystie Street tower, he jumped out of bed. , The photo speaks for itself. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Patients with higher levels ... a study published today in Nature Communications and led by researchers from the Icahn ... that variations in the gene RTN1 led to greater production of the related RNT1 ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3
... GPRO ) announced today that the Company will release ... 2008 at approximately,4:00 p.m. Eastern Time (ET). The announcement ... ET. Henry L. Nordhoff, chairman and chief,executive officer, and ... will host the call., The conference call will ...
... of $350K will Target Easter Seals Affiliates Nationwide, ... the emerging,challenges of people living with autism during April,s ... $350,000 in grants this,month from the CVS Caremark Charitable ... million to support Easter Seals autism services,nationwide. These grants ...
... heart, lungs and liver, study suggests , , THURSDAY, April ... fatty plaques that harden arteries may also harm vital ... formation in arteries," said study author Rita K. Upmacis, ... at Weill Medical College of Cornell University in New ...
... Decline Even Though Everyone Benefits ... Forget to Claim The Deduction!, NEW YORK, April 10 ... a timely reminder that donating your car is,still a great way ... that because the number of vehicle donations has plummeted -- and,charities ...
... with this method, researchers find , , THURSDAY, ... and vegetables can reduce the risk of food ... bacteria, new research shows. , The study suggests ... the U.S. Food and Drug Administration, can kill ...
... NEW YORK, April 10 Methodist Healthcare -- Memphis,Hospitals ... tender offer for certain designated maturities of the,Bonds. The ... was set to,expire on April 9, 2008 at 5:00 ... the tender offer will be terminated is applicable to,the ...
Cached Medicine News:Health News:Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call 2Health News:Easter Seals Receives $1 Million Donation From CVS Caremark Charitable Trust to Enhance Autism Services for Children 2Health News:Easter Seals Receives $1 Million Donation From CVS Caremark Charitable Trust to Enhance Autism Services for Children 3Health News:Atherosclerosis May Also Harm Vital Organs 2Health News:Atherosclerosis May Also Harm Vital Organs 3Health News:Tax Season Reminder: Vehicle Donations Still Needed 2Health News:Irradiation Almost Erases Risk of Food Poisoning 2Health News:Irradiation Almost Erases Risk of Food Poisoning 3Health News:Irradiation Almost Erases Risk of Food Poisoning 4Health News:Methodist Healthcare - Memphis Hospitals Announces Termination of Tender Offers 2
Curved tying forceps made of titanium has curved shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 103 mm....
Curved tying spring forceps made of titanium, delicate smooth jaws, length 10 mm, TCI jaws with round handle, diam. 8 mm and overall length 115 mm....
Thornton titanium curved suture tying forceps, 4"....
Round handle McPherson angled tying forceps with 10 mm tips and 5 mm titanium coated platforms. Length 110 mm....
Medicine Products: